While tumor necrosis factor (TNF) deficiency is associated with a higher incidence of tuberculosis, excessive production of TNF is associated with an exaggerated inflammatory response that can result in mycobacterial immune reconstitution inflammatory syndrome (IRIS).
Immune reconstitution inflammatory syndrome (IRIS) is a paradoxical clinical worsening of a known condition—or the appearance of a new condition—after a patient with HIV initiates antiretroviral therapy (ART). Frequently associated with mycobacteria, which can cause tuberculosis (TB), among other diseases, IRIS typically requires treatment with corticosteroids. However, patients’ clinical response to corticosteroid treatment is not always adequate, and that challenge has clinicians looking to anti—tumor necrosis factor (TNF) therapies for alternatives.
While TNF deficiency is associated with a higher incidence of TB, excessive production of TNF is associated with an exaggerated inflammatory response that can result in mycobacterial IRIS. A new case report published in Open Forum Infectious Diseases suggests that biosimilar infliximab, an anti-TNF, could provide a therapeutic option for patients whose IRIS is refractory to corticosteroids.
The case report first discusses Patient 1, a 33-year-old African American man who was diagnosed with HIV 3 months prior to being admitted to the hospital with a high fever, where a culture confirmed the presence of drug-sensitive Mycobacterium tuberculosis. After 3 weeks of anti-TB therapy, the patient initiated anti-HIV treatment with raltegravir, emtricitabine, and tenofovir. After 4 weeks, the patient developed a fever and enlarged lymph nodes. When Patient 1 did not show clinical improvement after treatment with naproxen and methylprednisolone, and other possible pathogens had been ruled out, the clinicians initiated treatment with biosimilar infliximab, CT-P13 at a dose of 5 mg/kg every 2 weeks for a total of 3 infusions.
During the third infusion, Patient 1 experienced an anaphylactic reaction despite premedication with hydrocortisone and paracetamol (the reaction was resolved with adrenaline, hydrocortisone, and infused saline solution). In the weeks following his treatment with biosimilar infliximab, Patient 1’s fever resolved and his lymph nodes were no longer palpable.
The authors also report on Patient 2, a 44-year-old white woman diagnosed with HIV in 2003 who had not taken ART in the 2 years prior to her 2015 admission to the hospital with fever and diarrhea—the fever resolved after anti-TB therapy. Several weeks later, a biopsy of her colon yielded Mycobacterium bovis. After 5 weeks of antimycobaterial therapy, Patient 2 initiated anti-HIV therapy, but developed abdominal pain and symptoms indicating partial obstruction of the intestine that required hospitalization. Patient 2’s symptoms resolved with methylprednisolone, but after tapering the corticosteroid, she required several subsequent hospitalizations for a return of the partial obstruction of the intestine.
Because the corticosteroid could not be withdrawn without worsening Patient 2’s condition, the clinicians initiated treatment with biosimilar infliximab (CT-P13, as with Patient 1) at 5 mg/kg every 2 weeks for a total of 3 infusions. Patient 2’s clinical condition improved, and laboratory values returned to normal with no indications of a relapse of mycobacterial disease. Methylprednisolone was tapered and eventually withdrawn 6 weeks after the first infliximab dose with no difficulty. No adverse events related to treatment with infliximab were recorded for Patient 2.
A meta-analysis of 40 studies and 1048 cases showed that tuberculosis-associated IRIS was reported in 18% of patients with HIV who were initiating ART, and that a 2% mortality rate and a 25% morbidity rate were directly attributable to TB-associated IRIS. “Treatment for the more severe and life-threatening clinical forms of IRIS has not undergone any innovative changes in recent decades beyond the use of corticosteroids,” the authors note. While their experience in using biosimilar infliximab with patients who have HIV is limited, and while Patient 1’s anaphylactic reaction to treatment is noteworthy, they believe that biosimilar infliximab could be a promising alternative for patients who have severe, corticosteroid-refractory mycobacterial IRIS.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.